ranQ
ranQ
ranQ
DirectoryIndustriesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The first Swiss company directory, built to boost AI visibility.

Product
  • Pricing
  • Directory
  • Industries
Company
  • About
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint742,807 companies indexed · Last updated: today
DirectoryBusiness & Technical ServicesResearch & DevelopmentAu ZhAraris Biotech AG
Araris Biotech AG Logo
Verified· 3 sources

Araris Biotech AG

Summary

About the company

Araris Biotech AG develops a proprietary linker technology for antibody–drug conjugates (ADCs) that enables one‑step enzymatic attachment of payloads to off‑the‑shelf antibodies without antibody re‑engineering. The platform targets a specific site (Q295) in the IgG‑Fc region to produce homogeneous, stable and water‑soluble ADCs, and the company advances an internal ADC pipeline while collaborating with external partners.

AI-generated
Offering

Products & services

Industry:Research & Development
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
✓ Offered4
ADC Linker Technology (AraLinQ®)
Peptide linker technology for site-specific conjugation of payloads to antibodies, one-step with „off-the-shelf“ antibodies; developed for stable, homogeneous and highly soluble Antibody-Drug Conjugates.
Development of Antibody-Drug Conjugates (ADCs)
Development of Antibody-Drug Conjugates for targeted delivery of active substances to cancer cells, with a focus on preclinical and clinical candidates.
ADC Pipeline Programs
Own ADC programs in Discovery, preclinical and Phase 1, including ARC-02 against CD79b as well as ARC-401 against Nectin-4 and ARC-201 against NaPi2b.
Research collaborations and licensing of ADC technology
Research collaborations as well as option and licensing agreements for the development of new ADCs with partners using the AraLinQ™ technology.
Press

Media

March 20, 2025Media
Bei mehr als eine Milliarde Umsatz: Das PSI-Spin-off Araris Biotech AG erreicht Bewertung auf Unicorn-Level
aargauerzeitung.ch
March 17, 2025Media
Taiho Pharmaceutical to acquire Araris Biotech for up to USD 1.1 billion
startupticker.ch
April 18, 2023Media
Araris expands its pipeline towards solid tumor indications
startupticker.ch

Knowledge

No knowledge articles yet

Once Araris Biotech AG has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

Araris Biotech AG in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank Araris Biotech AG by reviews, experience and specialisations.

Is this your company?

Claim the company profile of Araris Biotech AG to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Riedhofstrasse 11
8804 Au Zh

At a glance

Legal form
Corporation
UID
CHE-134.399.290
Founded
2019 · 7 years
Last commercial register change
May 7, 2025
Employees
1 to 10

Similar companies

AR
Akademische Raumfahrt Initiative Schweiz (ARIS)
Dübendorf
BS
BIO-TECHNOPARK Schlieren-Zürich
Schlieren
CA
Contrec AG
Dietikon
SR
Swiss Rescue Innovation GmbH
Wallisellen